One year after completion of all treatment, pre-planned interim subgroup analysis revealed that DFS prolongation in the bevacizumab arm was solely observed in patients with BRAFV600E mutant melanomas, with HR 0.06 (95% CI 0.43–0.85, p = 0.004) compared with HR 0.87 (95% CI 0.64–1.18, p = 0.36) in BRAF wild-type (BRAFWT) melanoma patients [11]. The gene discussed is BRAF; the disease is melanoma.